Japanese Firm Mitsui Invests In China's Hutchison MediPharma; First Step Toward An IPO?
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Hutchison MediPharma, one of China's leading biotechs, announced Nov. 8 that Tokyo-based venture capital firm Mitsui had acquired a 12.2 percent stake in the company for $12.5 million, generating speculation among China watchers that it could be a first step toward self-funding and an eventual IPO for Hutchison
You may also be interested in...
AstraZeneca Licenses Global Rights To Oncology Compound From China’s Hutchison
AstraZeneca pays $20 million up front to license Hutchison’s Phase I-ready compound in another sign that the U.K. pharma has its eyes set firmly on China.
China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market
SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market
China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market
SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market